IMGN
ImmunoGen, Inc. News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 1,
"returned": 1,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "74d9d553-18ef-4746-a57c-6785868f3201",
"title": "Global Ovarian Cancer Treatment Drugs Market Size To Exceed USD 5.45 Billion By 2033 | CAGR OF 8.10%",
"description": "The Global Ovarian Cancer Treatment Drugs Market Size was Valued at USD 2.50 Billion in 2023 and the Worldwide Ovarian Cancer Treatment Drugs Market Size...",
"keywords": "SPHERICAL INSIGHTS LLP, Ovarian Cancer Market, Cancer Treatment Drugs Market, Market Size, Market Share, Market Growth, Market Analysis, Trends, Market Price",
"snippet": "New York, United States, May 13, 2024 (GLOBE NEWSWIRE) -- The Global Ovarian Cancer Treatment Drugs Market Size is to Grow from USD 2.50 Billion in 2023 to USD ...",
"url": "https://www.globenewswire.com/news-release/2024/05/13/2880793/0/en/Global-Ovarian-Cancer-Treatment-Drugs-Market-Size-To-Exceed-USD-5-45-Billion-By-2033-CAGR-OF-8-10.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/b27a94e8-407e-46ae-a5c2-47bb2a1c8a2e",
"language": "en",
"published_at": "2024-05-13T18:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "IMGN",
"name": "ImmunoGen, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.49009,
"sentiment_score": 0.07655,
"highlights": [
{
"highlight": "., Clovis Oncology, <em>ImmunoGen</em>, <em>Inc</em>., AbbVie Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche AG, Vivesto AB, Merck KGaA, Oasmia Pharmaceutical AB, Bristol-Myers Squibb Company, Eli Lilly and Company, and Other Key Players.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Get Discount At @ https://www.sphericalinsights.com/request-discount/4241\n\nRecent Developments\n\nIn February 2024, AbbVie completed its acquisition of <em>ImmunoGen</em> <em>Inc</em>., which is now part of AbbVie, gaining its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant",
"sentiment": 0.1531,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "IMGN",
"total_documents": 1,
"sentiment_avg": 0.07654999941587448
}
]
}
Other details
Exchange
- NASDAQ Stock Exchange
- equity
- Healthcare
- us